PTEN and cancer: By targeting SP1, miR-29b can modulate PTEN expression and induce EMT via the miR-29b/PTEN/PI3K axis, and so promotes cancer cell motility, invasion, and chemoresistance to medicines such as cisplatin, paclitaxel, and docetaxel (Table A1) [61,62].